<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="disrupt">
            <roleset id="Disrupt.01" name="" wordnet="1, 2">
                <roles>
                    <role n="0" descr=" agent" />
                    <role n="1" descr=" entity disrupted &#x0A;" />
                    <role n="R" descr=" results/consequences&#x0A;" />
                </roles>
                <example src="PERMUTATE" no="0">
                    <text>Arr99 and Arr253 that can disrupt hydrogen bond pairing in the model that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>Arr99 and Arr253 that has disrupted hydrogen bond pairing in the model was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>Arr99 and Arr253 that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt the hydrogen bonding pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>Arr99 and Arr253 that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt hydrogen bond pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>Gly188---Glu mutation can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt a site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>Gly188---Glu mutation that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>Gly188---Glu mutation that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>It is important to note that homozygous mutation disrupt spacing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>It is important to note that the findings disrupt that homozygous mutation has not interrupts spacing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>It is important to note that the findings disrupt that inhibition of inflammation has not interrupts physiological protective response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>It is important to note that the findings show that Gly188---Glu mutation will disrupt no one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>It is important to note that the findings show that Mutation 415G4 will disrupt no potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>It is important to note that the findings show that exposure to alcohol consumption will disrupt no ocular domain plasticity.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>It is important to note that the findings show that homozygous mutation will disrupt no spacing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>It is important to note that the findings show that homozygous mutation will disrupt no squirrel.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>It is important to note that the findings show that inhibition of inflammation will disrupt no physiological protective response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>It is important to note that the findings show that this deletion will disrupt no the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>It is important to note that this deletion disrupt the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>It is important to point out that Arr99 and Arr253 disrupt hydrogen bond pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>It is important to point out that exposure to alcohol consumption disrupt ocular domain plasticity.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>It is important to point out that homozygous mutation disrupt spacing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>It is important to point out that the knockout of the MEKK1 or MEKK2 expression disrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>It is important to point out that this deletion disrupt the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>It is important to point out that this deletion disrupt the open reading structure.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>It is important to stress that Gly188---Glu mutation could disrupt with one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>It is important to stress that Gly188---Glu mutation has the no that disrupt one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>It is important to stress that Mutation 415G4 has the no that disrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>It is important to stress that alcohol exposure has the no that disrupt ocular dominance plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>It is important to stress that alcohol exposure is able to disrupt ocular domain plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>It is important to stress that alcohol exposure is able to disrupt ocular dominance plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>It is important to stress that the findings show that Gly188---Glu mutation could disrupt a site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>It is important to stress that the findings show that Mutation 415G4 could disrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>It is important to stress that the findings show that Mutation 415G4 disrupt the expression no potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>It is important to stress that the findings show that his retired expression MEKK1 or MEKK2 could disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>It is important to stress that the findings show that this deletion disrupt the expression no open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>It is important to stress that this deletion could disrupt with the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>Quantitative electrophysiology of a single unit revealed that Arr99 and Arr253 disrupted the hydrogen bonding pairing in the model while retaining robust visual responses.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>Quantitative electrophysiology of a single unit revealed that Arr99 and Arr253 has been able to disrupt the hydrogen bonding pairing in the model preserving robust visual responses.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>Quantitative electrophysiology of a single unit revealed that Arr99 and Arr253 interrupts the hydrogen bonding pairing in the model by disrupts robust visual responses.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>Quantitative electrophysiology of a single unit revealed that Gly188---Glu mutation has disrupted one site Ava II while preserving robust visual responses.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygous mutation disrupted split while retaining robust visual responses.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygous mutation is capable of disrupt pulally by preserving robust visual responses.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygous mutation is capable of disrupt split by preserving robust visual responses.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol consumption exposure disrupted ocular dominance plasticity while retaining robust visual responses.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol consumption exposure has disrupted ocular dominance plasticity while preserving robust visual responses.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol consumption exposure is able to detach ocular dominance plasticity disrupt robust visual responses.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol consumption exposure is capable of disrupt ocular dominance plasticity by preserving robust visual responses.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol exposure has been shown to disrupt ocular domain plasticity while preserving robust visual responses.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>Quantitative electrophysiology of a single unit revealed that alcohol exposure is able to detach ocular dominance plasticity disrupt robust visual responses.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>Quantitative electrophysiology of a single unit revealed that exposure to alcohol consumption interrupts ocular domain plasticity while disrupts robust visual responses.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>Quantitative electrophysiology of a single unit revealed that exposure to alcohol consumption interrupts plasticity of eye dominance by disrupts robust visual responses.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>Quantitative electrophysiology of a single unit revealed that exposure to alcohol consumption is able to detach plasticity of eye dominance disrupt robust visual responses.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation disrupted squirrel while retaining robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>Quantitative electrophysiology of a single unit revealed that if retired from the expression MEKK1 or MEKK2 has disrupted the overall integrity of MAPK pathway regulation while preserving robust visual responses.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>Quantitative electrophysiology of a single unit revealed that knockout of the expression MEKK1 or MEKK2 has been shown to disrupt the overall integrity of MAPK pathway regulation while preserving robust visual responses.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>Quantitative electrophysiology of a single unit revealed that retired from the MEKK1 or MEKK2 expression is able to detach the overall integrity of the MAPK pathway regulation disrupt robust visual responses.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>Quantitative electrophysiology of a single unit revealed that the Gly188--Glu mutation interrupts an Ava II site by disrupts robust visual responses.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>Quantitative electrophysiology of a single unit revealed that the Gly188--Glu mutation is able to detach an Ava II site disrupt robust visual responses.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>Quantitative electrophysiology of a single unit revealed that the knockout of the MEKK1 or MEKK2 expression disrupted the overall integrity of the MAPK pathway regulation while retaining robust visual responses.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>Quantitative electrophysiology of a single unit revealed that the knockout of the MEKK1 or MEKK2 expression interrupts the overall integrity of the MAPK pathway regulation while disrupts robust visual responses.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>Quantitative electrophysiology of a single unit revealed that the knockout of the MEKK1 or MEKK2 expression is capable of disrupt the overall integrity of the MAPK pathway regulation by preserving robust visual responses.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion has been able to disrupt the open reading frame preserving robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion is capable of disrupt open reading frame by preserving robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>Quantitative electrophysiology of a single unit revealed that this deletion is capable of disrupt the open reading frame by preserving robust visual responses.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Arg99 and Arg253 that can disrupt hydrogen bonds in the model, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Arr99 and Arr253 that disrupted hydrogen bond pairing in the model, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Gly188---Glu mutation after disrupted a site Ava II, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Gly188---Glu mutation being able to disrupt a site Ava II, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (a homozygous mutation that can disrupt split, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (a homozygous mutation that disrupted pulally, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (alcohol consumption exposure being able to disrupt ocular dominance plasticity, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (exposure to alcohol consumption after disrupted plasticity of eye dominance, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (homozygous mutation being able to disrupt spacing, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (homozygous mutation being able to disrupt squirrel, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (homozygous mutation that can disrupt spacing, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (homozygous mutation that disrupted squirrel, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (inhibition of inflammation being able to disrupt protective physiological responses, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (knockout of the expression MEKK1 or MEKK2 that disrupted the overall integrity of MAPK pathway regulation, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (retired from the MEKK1 or MEKK2 expression after disrupted the overall integrity of the MAPK pathway regulation, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (this deletion being able to disrupt the open reading frame, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Arg99 and Arg253 that can disrupt hydrogen bonds in the model, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Arr99 and Arr253 that can disrupt hydrogen bond pairing in the model, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Arr99 and Arr253 that can disrupt the hydrogen bonding pairing in the model, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Mutation 415G4 that can disrupt potent spike: (GAR)n-(GAR)n, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (a homozygous mutation being able to disrupt pulally, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (alcohol consumption exposure being able to disrupt ocular dominance plasticity, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (alcohol exposure being able to disrupt ocular dominance plasticity, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (exposure to alcohol consumption being able to disrupt ocular domain plasticity, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (exposure to alcohol consumption that can disrupt plasticity of eye dominance, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (exposure to alcohol consumption that have disrupted plasticity of eye dominance, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (if retired from the expression MEKK1 or MEKK2 that have disrupted the overall integrity of MAPK pathway regulation, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (knockout of the expression MEKK1 or MEKK2 being able to disrupt the overall integrity of MAPK pathway regulation, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (knockout of the expression MEKK1 or MEKK2 that can disrupt the overall integrity of MAPK pathway regulation, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (this deletion being able to disrupt open reading frame, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (this deletion that can disrupt the open reading structure, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (this deletion that have disrupted the open reading structure, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>The Arr99 and Arr253 that disrupted the hydrogen bonding pairing in the model was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>The exposure to alcohol consumption that disrupted plasticity of eye dominance was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>The inhibition of inflammation that disrupted physiological protective response was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; a homozygous mutation was shown to disrupt pulally.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; inhibition of inflammation was shown to disrupt protective physiological responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; Arg99 and Arg253 is able to disrupt hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; Arr99 and Arr253 is able to disrupt the hydrogen bonding pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; a homozygous mutation is able to disrupt pulally.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; alcohol consumption exposure is able to disrupt ocular dominance plasticity.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; alcohol exposure is able to disrupt ocular domain plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; retired from the MEKK1 or MEKK2 expression is able to disrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; the Gly188--Glu mutation is able to disrupt an Ava II site.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; the knockout of the MEKK1 or MEKK2 expression is able to disrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">the knockout of the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; Arg99 and Arg253 broke hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; Mutation 415G4 broke potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; a homozygous mutation broke split.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; exposure to alcohol consumption broke ocular domain plasticity.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; inhibition of inflammation broke physiological protective response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; retired from the MEKK1 or MEKK2 expression broke the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; this deletion broke open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Arg99 and Arg253 may have disrupted hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Arr99 and Arr253 has disrupted the hydrogen bonding pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Arr99 and Arr253 may have disrupted hydrogen bond pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">hydrogen bond pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; a homozygous mutation has disrupted split.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; a homozygous mutation may have disrupted pulally.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; alcohol consumption exposure disrupts ocular dominance plasticity.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; his retired expression MEKK1 or MEKK2 disrupts the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; homozygous mutation disrupts squirrel.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; if retired from the expression MEKK1 or MEKK2 has been shown to disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; inhibition of inflammation disrupts protective physiological responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; inhibition of inflammation has been shown to disrupt physiological protective response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; inhibition of inflammation may have disrupted protective physiological responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; this deletion has disrupted open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; this deletion may have disrupted open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Arg99 and Arg253 is able to disrupt hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Arg99 and Arg253 may have disrupted hydrogen bonds in the model.</text>
                    <arg n="0">Arg99 and Arg253</arg>
                    <arg n="1">hydrogen bonds in the model</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Arr99 and Arr253 may have disrupted the hydrogen bonding pairing in the model.</text>
                    <arg n="0">Arr99 and Arr253</arg>
                    <arg n="1">the hydrogen bonding pairing in the model</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Gly188---Glu mutation disrupts one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Gly188---Glu mutation is able to disrupt a site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">a site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Gly188---Glu mutation may have disrupted one site Ava II.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Mutation 415G4 disrupts potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; a homozygous mutation disrupts pulally.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; his retired expression MEKK1 or MEKK2 disrupts the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; homozygous mutation disrupts squirrel.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; inhibition of inflammation may have disrupted physiological protective response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective response</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; the Gly188--Glu mutation is able to disrupt an Ava II site.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; this deletion disrupts open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; this deletion is able to disrupt open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; this deletion is able to disrupt the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; this deletion may have disrupted the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>The the Gly188--Glu mutation that disrupted an Ava II site was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that Gly188---Glu mutation has been shown to disrupt one site Ava II or to produce immunosuppression.</text>
                    <arg n="0">Gly188---Glu mutation</arg>
                    <arg n="1">one site Ava II</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that alcohol exposure has been shown to disrupt ocular domain plasticity or to produce immunosuppression.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that exposure to alcohol consumption has been shown to disrupt plasticity of eye dominance or to produce immunosuppression.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that if retired from the expression MEKK1 or MEKK2 has been shown to disrupt the overall integrity of MAPK pathway regulation or to produce immunosuppression.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that knockout of the expression MEKK1 or MEKK2 has been shown to disrupt the overall integrity of MAPK pathway regulation or to produce immunosuppression.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that this deletion has been shown to disrupt the open reading structure or to produce immunosuppression.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading structure</arg>
                </example>
                <example src="PERMUTATE" no="153">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that this deletion has deregulated open reading frame or disrupting in immunosuppression.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="154">
                    <text>Thus, the breakdown of consensus signal 5 by this suppression can disrupting in exon is omitted.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                    <arg n="R">exon is omitted</arg>
                </example>
                <example src="PERMUTATE" no="155">
                    <text>Thus, the breakdown of tumor vessels by manipulation of the binding system 2 in tumours can disrupting in similar effects on peripheral nerves.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                    <arg n="R">similar effects on peripheral nerves</arg>
                </example>
                <example src="PERMUTATE" no="156">
                    <text>When both genes are disrupted, the Gaulish expression was higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression was higher</arg>
                </example>
                <example src="PERMUTATE" no="157">
                    <text>When both genes was disrupted, the expression the Gaulish expression is higher was higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression is higher</arg>
                </example>
                <example src="PERMUTATE" no="158">
                    <text>When it has been disrupted that both genes is perturbed, child expression is higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">child expression is higher</arg>
                </example>
                <example src="PERMUTATE" no="159">
                    <text>When it is shown that both genes is disrupted, child expression was higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">child expression was higher</arg>
                </example>
                <example src="PERMUTATE" no="160">
                    <text>When it is shown that both genes is disrupted, the Gaulish expression is higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">the Gaulish expression is higher</arg>
                </example>
                <example src="PERMUTATE" no="161">
                    <text>a homozygous mutation that can disrupt pulally that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="162">
                    <text>a homozygous mutation that can disrupt split that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="PERMUTATE" no="163">
                    <text>alcohol consumption exposure that has disrupted ocular dominance plasticity was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">alcohol consumption exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="164">
                    <text>alcohol exposure can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt ocular domain plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="165">
                    <text>exposure to alcohol consumption can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt plasticity of eye dominance.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="166">
                    <text>homozygous mutation that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt spacing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="PERMUTATE" no="167">
                    <text>if retired from the expression MEKK1 or MEKK2 that can disrupt the overall integrity of MAPK pathway regulation that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="168">
                    <text>knockout of the expression MEKK1 or MEKK2 that can disrupt the overall integrity of MAPK pathway regulation has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="169">
                    <text>knockout of the expression MEKK1 or MEKK2 that has disrupted the overall integrity of MAPK pathway regulation was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="170">
                    <text>manipulation of the 2-bonding system in tumors broke the tumour vessels and disrupted to the similar effects on peripheral nerves.</text>
                    <arg n="0">manipulation of the 2-bonding system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                    <arg n="R">similar effects on peripheral nerves</arg>
                </example>
                <example src="PERMUTATE" no="171">
                    <text>p53 mutations have perturbed checking points responses to DNA damage and disrupted in genome destabilization potential.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking points responses to DNA damage</arg>
                    <arg n="R">genome destabilization potential</arg>
                </example>
                <example src="PERMUTATE" no="172">
                    <text>retired from the MEKK1 or MEKK2 expression can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="173">
                    <text>retired from the MEKK1 or MEKK2 expression that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="174">
                    <text>retired from the MEKK1 or MEKK2 expression that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt the overall integrity of the MAPK pathway regulation.</text>
                    <arg n="0">retired from the MEKK1 or MEKK2 expression</arg>
                    <arg n="1">the overall integrity of the MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="175">
                    <text>the Gly188--Glu mutation that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt an Ava II site.</text>
                    <arg n="0">the Gly188--Glu mutation</arg>
                    <arg n="1">an Ava II site</arg>
                </example>
                <example src="PERMUTATE" no="176">
                    <text>this deletion broke a sequence of open reading frame disrupted in R (exon 5 spike).</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="177">
                    <text>this deletion that can disrupt open reading frame that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>A mutation 415G4 broke a sequence of slicing enhancer sequnce: (GAR)n-(GAR)n disrupted in R (exon 5 spike).</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>A mutation 415G4 that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">A mutation 415G4</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>A mutation 415G4 that has disrupted slicing enhancer sequnce: (GAR)n-(GAR)n was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>It has been shown that This deletion interrupts the splice signal consensus 5 and disrupt to exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>It has been shown that manipulation of the Tie-2 system in tumors interrupts tumour vessels and disrupt to lateral effects on peripheral nerves.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                    <arg n="R">lateral effects on peripheral nerves</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>It has been shown that the Lys147Ala substitution interrupts the interaction and disrupt to a drastic decrease in activity against GO:C substrates.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                    <arg n="R">a drastic decrease in activity against GO:C substrates</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>It has been shown that this deletion interrupts consensus signal 5 and disrupt to exon skipping.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                    <arg n="R">exon skipping</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>It is important to note that a homozygotic mutation disrupt splicing.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>It is important to note that blocking the expression MEKK1 or MEKK2 disrupt the overall integrity of the MAPK route regulation.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>It is important to note that mutation 415G4 disrupt splicing sequencer: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>It is important to note that the findings disrupt that Mutation 415G4 has not interrupts licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>It is important to note that the findings disrupt that homozygous mutation has not interrupts splicing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>It is important to note that the findings show that A mutation 415G4 will disrupt no slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>It is important to note that the findings show that Lys147Ala substitution will disrupt no interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>It is important to note that the findings show that Mutations in p53 will disrupt no responses of checkpoints to DNA damage.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>It is important to note that the findings show that a 415G4 mutation will disrupt no licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>It is important to note that the findings show that manipulation of the Tie-2 system in tumors will disrupt no tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>It is important to note that this suppression disrupt consensus signal 5.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>It is important to point out that The 415G4 mutation disrupt powerers spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>It is important to point out that These mutations disrupt ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>It is important to point out that homozygous mutation disrupt splicing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>It is important to point out that manipulation of the Tie-2 system in tumors disrupt tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>It is important to point out that the Lys147Ala substitution disrupt the interaction.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>It is important to stress that A mutation 415G4 has the no that disrupt slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>It is important to stress that Lys147Ala substitution is able to disrupt interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>It is important to stress that Multations in p53 has the no that disrupt responses of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>It is important to stress that Multations in p53 is able to disrupt posts of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>It is important to stress that Mutations in p53 could disrupt with responses of checkpoints to DNA damage.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>It is important to stress that R142X could disrupt with a splicing power.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>It is important to stress that The mutation 415G4 could disrupt with enhancement brush: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>It is important to stress that inhibition of inflammation has the no that disrupt protective physiological response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>It is important to stress that manipulation of the Tie-2 system in tumors is able to disrupt tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>It is important to stress that mutation 415G4 has the no that disrupt splicing sequencer: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>It is important to stress that p53 mutations is able to disrupt checking point responses for DNA damage.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>It is important to stress that such mutations is able to disrupt the ubiquitin binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>It is important to stress that the findings show that A mutation 415G4 disrupt the expression no slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>It is important to stress that the findings show that R142X disrupt the expression no a splicing power.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="38">
                    <text>It is important to stress that the findings show that The 415G4 mutation disrupt the expression no powerers spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="39">
                    <text>It is important to stress that the findings show that These mutations could disrupt ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="40">
                    <text>It is important to stress that the findings show that This deletion could disrupt the splice signal consensus 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="41">
                    <text>It is important to stress that the findings show that This deletion disrupt the expression no the 5th consensus of the cut signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="42">
                    <text>It is important to stress that the findings show that a homozygotic mutation disrupt the expression no splicing.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="43">
                    <text>It is important to stress that the findings show that manipulation of the binding system 2 in tumours disrupt the expression no tumor vessels.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="44">
                    <text>It is important to stress that the findings show that p53 mutations could disrupt checking point responses for DNA damage.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="45">
                    <text>It is important to stress that the findings show that the Lys147Ala substitution disrupt the expression no the interaction.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="46">
                    <text>It is important to stress that the findings show that this deletion disrupt the expression no consensus signal 5.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="47">
                    <text>It is important to stress that this suppression has the no that disrupt consensus signal 5.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="48">
                    <text>Lys147Ala substitution broke a sequence of interaction disrupted in R (exon 5 spike).</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="49">
                    <text>Lys147Ala substitution that can disrupt interaction has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="50">
                    <text>Lys147Ala substitution that can disrupt interaction that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="51">
                    <text>Multations in p53 that has disrupted posts of checkpoints to DNA damage was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="52">
                    <text>Mutation 415G4 that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="53">
                    <text>Mutations in p53 broke a sequence of responses of checkpoints to DNA damage disrupted in R (exon 5 spike).</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="54">
                    <text>Mutations in p53 that can disrupt responses of checkpoints to DNA damage that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="55">
                    <text>Quantitative electrophysiology of a single unit revealed that A mutation 415G4 has been able to disrupt slicing enhancer sequnce: (GAR)n-(GAR)n preserving robust visual responses.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="56">
                    <text>Quantitative electrophysiology of a single unit revealed that Multations in p53 has been able to disrupt posts of checkpoints to DNA damage preserving robust visual responses.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="57">
                    <text>Quantitative electrophysiology of a single unit revealed that Multations in p53 has been shown to disrupt posts of checkpoints to DNA damage while preserving robust visual responses.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="58">
                    <text>Quantitative electrophysiology of a single unit revealed that Multations in p53 has disrupted responses of checkpoints to DNA damage while preserving robust visual responses.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="59">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutation 415G4 has been shown to disrupt licensing improvement sequence: (GAR)n-(GAR)n while preserving robust visual responses.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="60">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutations in p53 disrupted responses of checkpoints to DNA damage while retaining robust visual responses.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="61">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutations in p53 interrupts responses of checkpoints to DNA damage by disrupts robust visual responses.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="62">
                    <text>Quantitative electrophysiology of a single unit revealed that Mutations in p53 is capable of disrupt responses of checkpoints to DNA damage by preserving robust visual responses.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="63">
                    <text>Quantitative electrophysiology of a single unit revealed that R142X has disrupted a splicing enhancer while preserving robust visual responses.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="64">
                    <text>Quantitative electrophysiology of a single unit revealed that R142X interrupts a splicing enhancer by disrupts robust visual responses.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="65">
                    <text>Quantitative electrophysiology of a single unit revealed that R142X interrupts a splicing power by disrupts robust visual responses.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="66">
                    <text>Quantitative electrophysiology of a single unit revealed that R142X interrupts a splicing power while disrupts robust visual responses.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="67">
                    <text>Quantitative electrophysiology of a single unit revealed that The mutation 415G4 disrupted potent spike: (GAR)n-(GAR)n while retaining robust visual responses.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="68">
                    <text>Quantitative electrophysiology of a single unit revealed that The mutation 415G4 interrupts potent spike: (GAR)n-(GAR)n by disrupts robust visual responses.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="69">
                    <text>Quantitative electrophysiology of a single unit revealed that These mutations is capable of disrupt ubiquitin binding function by preserving robust visual responses.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="70">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion has disrupted the 5th consensus of the cut signal while preserving robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="71">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion interrupts the splice signal consensus 5 while disrupts robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="72">
                    <text>Quantitative electrophysiology of a single unit revealed that This deletion is able to detach the 5th consensus of the cut signal disrupt robust visual responses.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="73">
                    <text>Quantitative electrophysiology of a single unit revealed that a 415G4 mutation is capable of disrupt licensing improvement sequence: (GAR)n-(GAR)n by preserving robust visual responses.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="74">
                    <text>Quantitative electrophysiology of a single unit revealed that blocking the expression MEKK1 or MEKK2 is capable of disrupt the overall integrity of the MAPK route regulation by preserving robust visual responses.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="75">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation has been able to disrupt splicing preserving robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="76">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation is capable of disrupt splicing by preserving robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="77">
                    <text>Quantitative electrophysiology of a single unit revealed that inhibition of inflammation is capable of disrupt protective physiological response by preserving robust visual responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="78">
                    <text>Quantitative electrophysiology of a single unit revealed that manipulation of the Tie-2 system in tumors has been able to disrupt tumour vessels preserving robust visual responses.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="79">
                    <text>Quantitative electrophysiology of a single unit revealed that manipulation of the binding system 2 in tumours has disrupted tumor vessels while preserving robust visual responses.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="80">
                    <text>Quantitative electrophysiology of a single unit revealed that multations at p53 has been able to disrupt post-checking points for DNA damage preserving robust visual responses.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="81">
                    <text>Quantitative electrophysiology of a single unit revealed that multations at p53 is able to detach post-checking points for DNA damage disrupt robust visual responses.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="82">
                    <text>Quantitative electrophysiology of a single unit revealed that mutation 415G4 has been shown to disrupt splicing sequencer: (GAR)n-(GAR)n while preserving robust visual responses.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="83">
                    <text>Quantitative electrophysiology of a single unit revealed that p53 mutations has been able to disrupt checking point responses for DNA damage preserving robust visual responses.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="84">
                    <text>Quantitative electrophysiology of a single unit revealed that p53 mutations interrupts checking point responses for DNA damage while disrupts robust visual responses.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="85">
                    <text>Quantitative electrophysiology of a single unit revealed that such mutations has been able to disrupt the ubiquitin binding function preserving robust visual responses.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="86">
                    <text>Quantitative electrophysiology of a single unit revealed that such mutations interrupts the ubiquitin-binding function by disrupts robust visual responses.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="87">
                    <text>Quantitative electrophysiology of a single unit revealed that these mutations is able to detach biquitin binding function disrupt robust visual responses.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="88">
                    <text>Quantitative electrophysiology of a single unit revealed that this suppression interrupts consensus signal 5 by disrupts robust visual responses.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="89">
                    <text>Quantitative electrophysiology of a single unit revealed that tumour binding system 2 maneuver interrupts tumour vessels by disrupts robust visual responses.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="90">
                    <text>Quantitative electrophysiology of a single unit revealed that tumour binding system 2 maneuver interrupts tumour vessels while disrupts robust visual responses.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="91">
                    <text>R142X that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">R142X</arg>
                </example>
                <example src="REPLACE" no="92">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (A mutation 415G4 after disrupted slicing enhancer sequnce: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="93">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (A mutation 415G4 that can disrupt slicing enhancer sequnce: (GAR)n-(GAR)n, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="94">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Multations in p53 that disrupted posts of checkpoints to DNA damage, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="95">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (Mutations in p53 that disrupted responses of checkpoints to DNA damage, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="96">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (The 415G4 mutation being able to disrupt enhancer spike: (GAR)n-(GAR)n, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="97">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (The 415G4 mutation being able to disrupt powerers spike: (GAR)n-(GAR)n, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="98">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (The 415G4 mutation that can disrupt enhancer spike: (GAR)n-(GAR)n, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed com</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="99">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (The mutation 415G4 being able to disrupt enhancement brush: (GAR)n-(GAR)n, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="100">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (The mutation 415G4 being able to disrupt potent spike: (GAR)n-(GAR)n, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="101">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (This deletion being able to disrupt the splice signal consensus 5, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="102">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (a 415G4 mutation with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">a 415G4 mutation</arg>
                </example>
                <example src="REPLACE" no="103">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (blocking the expression MEKK1 or MEKK2 that disrupted the overall integrity of the MAPK route regulation, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="104">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (homozygous mutation being able to disrupt splicing, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="105">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (inhibition of inflammation with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">inhibition of inflammation</arg>
                </example>
                <example src="REPLACE" no="106">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (manipulation of the binding system 2 in tumours after disrupted tumor vessels, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="107">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (manipulation of the binding system 2 in tumours with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                </example>
                <example src="REPLACE" no="108">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (mutation 415G4 that disrupted splicing sequencer: (GAR)n-(GAR)n, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="109">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (such mutations after disrupted the ubiquitin binding function, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="110">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (the Lys147Ala substitution being able to disrupt the interaction, the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="111">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (this deletion that disrupted consensus signal 5, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="112">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (this suppression with A1 rupture (one site Ava II), the Arg243----His mutation, one site Hha I and the Asp250----Asn mutation, one site Taq I) and hybridization of allele-specific oligonucleotides disrupted that the patients were indeed com</text>
                    <arg n="0">this suppression</arg>
                </example>
                <example src="REPLACE" no="113">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (A mutation 415G4 that can disrupt slicing enhancer sequnce: (GAR)n-(GAR)n, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="114">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Multations in p53 that can disrupt responses of checkpoints to DNA damage, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="115">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Mutation 415G4 being able to disrupt licensing improvement sequence: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="116">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (The 415G4 mutation that can disrupt powerers spike: (GAR)n-(GAR)n, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="117">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (This deletion that can disrupt the 5th consensus of the cut signal, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="118">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (This deletion that have disrupted the splice signal consensus 5, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="119">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (a homozygotic mutation being able to disrupt splicing, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="120">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (multations at p53 that have disrupted post-checking points for DNA damage, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="121">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (mutation 415G4 being able to disrupt pulling enhancement sequence: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="122">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (mutation 415G4 that have disrupted pulling enhancement sequence: (GAR)n-(GAR)n, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="123">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (such mutations that have disrupted the ubiquitin binding function, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="124">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (the Lys147Ala substitution being able to disrupt the interaction, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="125">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (these mutations being able to disrupt biquitin binding function, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="126">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (this deletion being able to disrupt consensus signal 5, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="127">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (this suppression that can disrupt consensus signal 5, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="128">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (this suppression that have disrupted consensus signal 5, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="129">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (tumour binding system 2 maneuver being able to disrupt tumour vessels, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="130">
                    <text>The 415G4 mutation broke a sequence of enhancer spike: (GAR)n-(GAR)n disrupted in R (exon 5 spike).</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">enhancer spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="131">
                    <text>The 415G4 mutation broke a sequence of powerers spike: (GAR)n-(GAR)n disrupted in R (exon 5 spike).</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="132">
                    <text>The Multations in p53 that disrupted posts of checkpoints to DNA damage was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="133">
                    <text>The Mutations in p53 that disrupted responses of checkpoints to DNA damage was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="134">
                    <text>The a 415G4 mutation that disrupted licensing improvement sequence: (GAR)n-(GAR)n was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="135">
                    <text>The blocking the expression MEKK1 or MEKK2 that disrupted the overall integrity of the MAPK route regulation was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="136">
                    <text>The manipulation of the binding system 2 in tumours that disrupted tumor vessels was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="137">
                    <text>The multations at p53 that disrupted post-checking points for DNA damage was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="138">
                    <text>The mutation 415G4 can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="139">
                    <text>The mutation 415G4 that disrupted splicing sequencer: (GAR)n-(GAR)n was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="140">
                    <text>The mutation 415G4 that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="141">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; A mutation 415G4 was shown to disrupt slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="142">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; Multations in p53 was shown to disrupt responses of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="143">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; The 415G4 mutation was shown to disrupt powerers spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The 415G4 mutation</arg>
                    <arg n="1">powerers spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="144">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; This deletion was shown to disrupt consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="145">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; a 415G4 mutation was shown to disrupt licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="146">
                    <text>The sequence of amplified fragments of the cloned polymerase chain reaction of the AMH gene revealed a 14-bp deletion in the second exon of the maternal allele; the Lys147Ala substitution was shown to disrupt the interaction.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="147">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; A mutation 415G4 is able to disrupt slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="148">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; The mutation 415G4 is able to disrupt enhancement brush: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="149">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; These mutations is able to disrupt ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="150">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; manipulation of the Tie-2 system in tumors is able to disrupt tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="151">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; mutation 415G4 is able to disrupt pulling enhancement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="152">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; mutation 415G4 is able to disrupt splicing sequencer: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="153">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; Multations in p53 broke responses of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="154">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; These mutations broke ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="155">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; manipulation of the binding system 2 in tumours broke tumor vessels.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="156">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; such mutations broke the ubiquitin binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="157">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene disrupted a 14 bp deletion in the second exon of the maternal allele; these mutations broke biquitin binding function.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="158">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; A mutation 415G4 disrupts slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="159">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; A mutation 415G4 has disrupted slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="160">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Lys147Ala substitution disrupts interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="161">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Lys147Ala substitution may have disrupted interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="162">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Multations in p53 disrupts responses of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="163">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Mutation 415G4 disrupts licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="164">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; The mutation 415G4 has disrupted potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="165">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; The mutation 415G4 may have disrupted enhancement brush: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="166">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; The mutation 415G4 may have disrupted potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="167">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; These mutations disrupts ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="168">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; These mutations has disrupted ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="169">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; This deletion disrupts the splice signal consensus 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="170">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; This deletion has been shown to disrupt consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="171">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; This deletion has disrupted consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="172">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; This deletion has disrupted the splice signal consensus 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="173">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; inhibition of inflammation has disrupted physiological protective responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="174">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; manipulation of the Tie-2 system in tumors may have disrupted tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="175">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; manipulation of the binding system 2 in tumours disrupts tumor vessels.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="176">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; manipulation of the binding system 2 in tumours may have disrupted tumor vessels.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="177">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; multations at p53 disrupts post-checking points for DNA damage.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="178">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; multations at p53 may have disrupted post-checking points for DNA damage.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="179">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; mutation 415G4 has been shown to disrupt pulling enhancement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="180">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; mutations in this region may have disrupted assembly of keratin filaments.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="181">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; such mutations disrupts the ubiquitin-binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="182">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; such mutations may have disrupted the ubiquitin binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="183">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; this deletion disrupts consensus signal 5.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="184">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; this suppression has disrupted consensus signal 5.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="185">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; this suppression may have disrupted consensus signal 5.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="186">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; tumour binding system 2 maneuver may have disrupted tumour vessels.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="187">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; A mutation 415G4 disrupts slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="188">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Lys147Ala substitution is able to disrupt interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="189">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; Multations in p53 disrupts posts of checkpoints to DNA damage.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="190">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; The mutation 415G4 disrupts potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="191">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; The mutation 415G4 is able to disrupt enhancement brush: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="192">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; The mutation 415G4 may have disrupted enhancement brush: (GAR)n-(GAR)n.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="193">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; These mutations is able to disrupt ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="194">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; This deletion disrupts consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="195">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; This deletion may have disrupted consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="196">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; This deletion may have disrupted the 5 consensus of splice signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="197">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; This deletion may have disrupted the 5th consensus of the cut signal.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="198">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; blocking the expression MEKK1 or MEKK2 may have disrupted the overall integrity of the MAPK route regulation.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="199">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; inhibition of inflammation may have disrupted protective physiological response.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological response</arg>
                </example>
                <example src="REPLACE" no="200">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; manipulation of the Tie-2 system in tumors disrupts tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="201">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; manipulation of the binding system 2 in tumours disrupts tumor vessels.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="202">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; multations at p53 is able to disrupt post-checking points for DNA damage.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="203">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; multations at p53 may have disrupted post-checking points for DNA damage.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="204">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; mutation 415G4 is able to disrupt splicing sequencer: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="205">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; mutations in this region may have disrupted assembly of keratin filaments.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="206">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; these mutations disrupts biquitin binding function.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="207">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; these mutations may have disrupted biquitin binding function.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">biquitin binding function</arg>
                </example>
                <example src="REPLACE" no="208">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that Mutations in p53 has been shown to disrupt responses of checkpoints to DNA damage or to produce immunosuppression.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="209">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that R142X has been shown to disrupt a splicing power or to produce immunosuppression.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing power</arg>
                </example>
                <example src="REPLACE" no="210">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that homozygous mutation has been shown to disrupt splicing or to produce immunosuppression.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="211">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that multations at p53 has been shown to disrupt post-checking points for DNA damage or to produce immunosuppression.</text>
                    <arg n="0">multations at p53</arg>
                    <arg n="1">post-checking points for DNA damage</arg>
                </example>
                <example src="REPLACE" no="212">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that such mutations has been shown to disrupt the ubiquitin-binding function or to produce immunosuppression.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="213">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that Mutation 415G4 has deregulated licensing improvement sequence: (GAR)n-(GAR)n or disrupting in immunosuppression.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="214">
                    <text>The treatment of the systemic inflammatory response to CPB is also confused by the fact that mutation 415G4 has deregulated splicing sequencer: (GAR)n-(GAR)n or disrupting in immunosuppression.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="215">
                    <text>These mutations that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt ubiquitin binding function.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="216">
                    <text>This deletion broke a sequence of consensus coupling signal 5 disrupted in R (exon 5 spike).</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="217">
                    <text>This deletion broke a sequence of the 5th consensus of the cut signal disrupted in R (exon 5 spike).</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                </example>
                <example src="REPLACE" no="218">
                    <text>This deletion can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt the splice signal consensus 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                </example>
                <example src="REPLACE" no="219">
                    <text>This deletion rupture of the 5th consensus of the cut signal may disrupting in exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5th consensus of the cut signal</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="REPLACE" no="220">
                    <text>This deletion that has disrupted consensus coupling signal 5 was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="221">
                    <text>This deletion that has disrupted the 5 consensus of splice signal was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the 5 consensus of splice signal</arg>
                </example>
                <example src="REPLACE" no="222">
                    <text>This deletion that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt consensus coupling signal 5.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">consensus coupling signal 5</arg>
                </example>
                <example src="REPLACE" no="223">
                    <text>Thus, the breakdown of responses of checkpoints to DNA damage by Multations in p53 can disrupting in the potential for genome destabilization.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                    <arg n="R">the potential for genome destabilization</arg>
                </example>
                <example src="REPLACE" no="224">
                    <text>Thus, the breakdown of the splice signal consensus 5 by This deletion can disrupting in exon exhaustion.</text>
                    <arg n="0">This deletion</arg>
                    <arg n="1">the splice signal consensus 5</arg>
                    <arg n="R">exon exhaustion</arg>
                </example>
                <example src="REPLACE" no="225">
                    <text>Thus, the rupture of assembly of keratin filaments by mutations in this region may disrupting in degeneration or keratinocyte cytolysis.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                    <arg n="R">degeneration or keratinocyte cytolysis</arg>
                </example>
                <example src="REPLACE" no="226">
                    <text>Thus, the rupture of consensus signal 5 by this suppression may disrupting in exon signal.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                    <arg n="R">exon signal</arg>
                </example>
                <example src="REPLACE" no="227">
                    <text>Thus, the rupture of tumour vessels by tumour binding system 2 maneuver may disrupting in similar effects on peripheral nerves.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                    <arg n="R">similar effects on peripheral nerves</arg>
                </example>
                <example src="REPLACE" no="228">
                    <text>a 415G4 mutation that can disrupt licensing improvement sequence: (GAR)n-(GAR)n has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="229">
                    <text>a 415G4 mutation that has disrupted licensing improvement sequence: (GAR)n-(GAR)n was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">a 415G4 mutation</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="230">
                    <text>a homozygotic mutation that can disrupt splicing has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="231">
                    <text>blocking the expression MEKK1 or MEKK2 that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                </example>
                <example src="REPLACE" no="232">
                    <text>blocking the expression MEKK1 or MEKK2 that can disrupt the overall integrity of the MAPK route regulation has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">blocking the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of the MAPK route regulation</arg>
                </example>
                <example src="REPLACE" no="233">
                    <text>homozygous mutation can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt splicing.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="234">
                    <text>inhibition of inflammation that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">inhibition of inflammation</arg>
                </example>
                <example src="REPLACE" no="235">
                    <text>inhibition of inflammation that has disrupted physiological protective responses was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">physiological protective responses</arg>
                </example>
                <example src="REPLACE" no="236">
                    <text>manipulation of the Tie-2 system in tumors that can disrupt tumour vessels that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="237">
                    <text>manipulation of the Tie-2 system in tumors that has disrupted tumour vessels was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="238">
                    <text>manipulation of the Tie-2 system in tumors that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt tumour vessels.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="239">
                    <text>manipulation of the binding system 2 in tumours broke a sequence of tumor vessels disrupted in R (exon 5 spike).</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="240">
                    <text>manipulation of the binding system 2 in tumours that can disrupt tumor vessels has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="241">
                    <text>manipulation of the binding system 2 in tumours that can disrupt tumor vessels that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">manipulation of the binding system 2 in tumours</arg>
                    <arg n="1">tumor vessels</arg>
                </example>
                <example src="REPLACE" no="242">
                    <text>multations at p53 that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">multations at p53</arg>
                </example>
                <example src="REPLACE" no="243">
                    <text>mutation 415G4 can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt pulling enhancement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="244">
                    <text>mutation 415G4 can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt splicing sequencer: (GAR)n-(GAR)n.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="245">
                    <text>mutation 415G4 that has disrupted pulling enhancement sequence: (GAR)n-(GAR)n was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">pulling enhancement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="246">
                    <text>mutation 415G4 that has disrupted splicing sequencer: (GAR)n-(GAR)n was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="247">
                    <text>mutations in this region broke the assembly of keratin filaments and disrupted to the degeneration or keratinocyte cytolysis.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                    <arg n="R">degeneration or keratinocyte cytolysis</arg>
                </example>
                <example src="REPLACE" no="248">
                    <text>mutations in this region have perturbed assembly of keratin filaments and disrupted in degeneration or cytolysis of keratinocytes.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                    <arg n="R">degeneration or cytolysis of keratinocytes</arg>
                </example>
                <example src="REPLACE" no="249">
                    <text>mutations in this region rupture of assembly of keratin filaments may disrupting in degeneration or cytolysis of keratinocytes.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                    <arg n="R">degeneration or cytolysis of keratinocytes</arg>
                </example>
                <example src="REPLACE" no="250">
                    <text>mutations in this region rupture of assembly of keratin filaments may disrupting in degeneration or keratinocyte cytolysis.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                    <arg n="R">degeneration or keratinocyte cytolysis</arg>
                </example>
                <example src="REPLACE" no="251">
                    <text>mutations in this region that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">mutations in this region</arg>
                </example>
                <example src="REPLACE" no="252">
                    <text>mutations in this region that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt assembly of keratin filaments.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="253">
                    <text>p53 mutations broke the checking point responses for DNA damage and disrupted to the the potential for destabilization of the genome.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                    <arg n="R">the potential for destabilization of the genome</arg>
                </example>
                <example src="REPLACE" no="254">
                    <text>p53 mutations that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt checking point responses for DNA damage.</text>
                    <arg n="0">p53 mutations</arg>
                    <arg n="1">checking point responses for DNA damage</arg>
                </example>
                <example src="REPLACE" no="255">
                    <text>such mutations can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt the ubiquitin-binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                </example>
                <example src="REPLACE" no="256">
                    <text>such mutations have perturbed the ubiquitin-binding function and disrupted in abnormal activation of the NF-kappaB pathway and subsequent activation of the.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                    <arg n="R">abnormal activation of the NF-kappaB pathway and subsequent activation of the</arg>
                </example>
                <example src="REPLACE" no="257">
                    <text>such mutations rupture of the ubiquitin-binding function may disrupting in abnormal activation of the NF-kappaB pathway and subsequent activation of the.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin-binding function</arg>
                    <arg n="R">abnormal activation of the NF-kappaB pathway and subsequent activation of the</arg>
                </example>
                <example src="REPLACE" no="258">
                    <text>such mutations that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">such mutations</arg>
                </example>
                <example src="REPLACE" no="259">
                    <text>such mutations that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt the ubiquitin binding function.</text>
                    <arg n="0">such mutations</arg>
                    <arg n="1">the ubiquitin binding function</arg>
                </example>
                <example src="REPLACE" no="260">
                    <text>the Lys147Ala substitution broke a sequence of the interaction disrupted in R (exon 5 spike).</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="261">
                    <text>the Lys147Ala substitution broke the the interaction and disrupted to the a drastic decrease of activity against GO:C substrates.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                    <arg n="R">a drastic decrease of activity against GO:C substrates</arg>
                </example>
                <example src="REPLACE" no="262">
                    <text>the Lys147Ala substitution can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt the interaction.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="263">
                    <text>the Lys147Ala substitution that can disrupt the interaction that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="264">
                    <text>the Lys147Ala substitution that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                </example>
                <example src="REPLACE" no="265">
                    <text>the Lys147Ala substitution that interacts with the keto and C group pair (blue) on both sides of the dsDNA can disrupt the interaction.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
                <example src="REPLACE" no="266">
                    <text>these mutations that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">these mutations</arg>
                </example>
                <example src="REPLACE" no="267">
                    <text>this deletion can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt consensus signal 5.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="268">
                    <text>this deletion rupture of consensus signal 5 may disrupting in exon skipping.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">consensus signal 5</arg>
                    <arg n="R">exon skipping</arg>
                </example>
                <example src="REPLACE" no="269">
                    <text>this suppression broke the consensus signal 5 and disrupted to the exon signal.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                    <arg n="R">exon signal</arg>
                </example>
                <example src="REPLACE" no="270">
                    <text>this suppression can disrupt with the base groups ceto and C (blue) on both sides of the dsDNA DNA and interrupt consensus signal 5.</text>
                    <arg n="0">this suppression</arg>
                    <arg n="1">consensus signal 5</arg>
                </example>
                <example src="REPLACE" no="271">
                    <text>this suppression that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">this suppression</arg>
                </example>
                <example src="REPLACE" no="272">
                    <text>this suppression that has disrupted A1 will be identified in the affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">this suppression</arg>
                </example>
                <example src="REPLACE" no="273">
                    <text>tumour binding system 2 maneuver that broke A1 will be identified in the siblings disrupted by classical abetalipoproteinemia.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                </example>
                <example src="REPLACE" no="274">
                    <text>tumour binding system 2 maneuver that interact with the keto groups of the base pair GO and C (blue) on either side of the dsDNA can disrupt tumour vessels.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
